Rapid Microbial Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rapid Microbial Testing
In this technical forum, experts describe different methods of rapid microbial testing and their applications.


Pharmaceutical Technology
Volume 36, Issue 5, pp. s14-s19

Results. Both methods were used to detect bacteria in Chinese hamster ovary (CHO) cell cultures. Epifluorescence microscopy was limited by filterability, media interference, and nonrobustness issues, whereas microcolonies fluorescent staining method enabled consistent detection of Bacillus cereus, Staphylococcus epidermidis, and Propionibacterium acnes after eight, nine, and 48 hours of incubation.


FIgure 2
With epifluorescence microscopy, nonspiked treated CHO cells yielded a great deal of fluorescent debris and a very high background (see Figure 2A), which interferes with the detection of B. cereus (see Figure 2B). Because observation was difficult in the presence of cells, B. cereus was spiked in CHO medium. The fluorescent background was removed, but it was still difficult to observe bacteria on the polycarbonate filter. The detection of the microorganisms was only possible when increasing the number of contaminants retained on the filter by tenfold (see Figure 2C). Microorganisms spiked in the mammalian cell culture were easily detected with the MFSM without any background or media interference (see Figure 2, D–F). Background noise was minimized as a result of lysing the CHO cells before the filtration using the mammalian cell lysis solution; this buffer eliminates CHO cells while minimizing the impact on microorganisms. Similar results were obtained for both methods with S. epidermidis and P. acnes (data not shown).

As a result of the nondestructive feature of the MFSM, stained membranes could be reincubated on culture media to yield visible colonies that can be collected for further identification using existing identification methodologies (i.e., biochemical, morphological, nucleic-acid analytics, etc.). The ability to identify the microorganism can accelerate the root cause analysis and implementation of the corrective/preventative action (CAPA) plan.

References

1. A. Onadipe and K. Ulvedal, PDA J. Pharm. Sci. Technol. 55, 337–345 (2001).

2. R.T. Noble and S.B. Weisberg, J. Water Health 3, 381–392 (2005).

3. S. Flint et al., J. Appl. Microbiol. 102, 909–915 (2007).

4. R. Chollet et al., J. Rapid Methods Autom. Microbiol. 16, 256–272 (2008).

5. U. M. Rodrigues and R.G. Kroll, J. Appl. Bacteriol. 59, 493–499 (1985).

6. J. Moldenhauer, (2008) "Overview of rapid microbiological methods" in Principles of Bacterial Detection: Biosensors, Recognition Receptors and Microsystems M. Zourob, S. Elwary, and A. Turner, Eds. (Springer New York, 2008) pp. 49–79.

7. Y. Motoyama et al., Transfusion 48, 2364–2369 (2008).

8. Y. Motoyama et al., J. Health Sci. 55, 726–731 (2009).

9. J.T. Lisle et al., Appl. Environ. Microbiol. 70, 5343–5348 (2004).

10. K. Mignon-Godefroy, J.G. Guillet, and C. Butor, Cytometry 27, 336–344 (1997).

11. S. Asano et al., J. Biosci. Bioeng. 108, 124–129 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here